Background: Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers. for which PARP inhibitors (PARPi) are becoming a preferred treatment option. However. a considerable proportion of these carcinomas acquire resistance or harbour de novo resistance. https://www.markymarkscott.com/product-category/mystic-magenta/